drugset / Trial / NCT00107770
Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)
Phase 1/2
Completed
40 enrolled
US Department of Veterans Affairs
Muscular Dystrophy Association · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety of sodium phenylbutyrate (NaPB) treatment in subjects with amyotrophic lateral sclerosis (ALS) and the ability to take this medication without major side effects.
Timeline
- Start
- 2005-04
- Primary completion
- 2006-11
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Phenylbutyrate | Small molecule | 21 g | Oral |